[{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"528148f0-7c78-4216-a985-523ee0a69663","acronym":"","url":"https://clinicaltrials.gov/study/NCT05388370","created_at":"2022-05-24T11:54:01.246Z","updated_at":"2025-02-25T13:54:27.531Z","phase":"","brief_title":"PASS of Paediatric Patients Initiating Selumetinib","source_id_and_acronym":"NCT05388370","lead_sponsor":"AstraZeneca","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 05/23/2022","start_date":" 05/23/2022","primary_txt":" Primary completion: 05/23/2028","primary_completion_date":" 05/23/2028","study_txt":" Completion: 05/23/2028","study_completion_date":" 05/23/2028","last_update_posted":"2025-02-20"},{"id":"9746c38a-e183-480a-bcc4-ea83361a9977","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554328","created_at":"2022-09-26T14:56:09.383Z","updated_at":"2025-02-25T13:49:33.072Z","phase":"Phase 2","brief_title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554328","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-20"},{"id":"6b0d9c50-7878-4173-9cf8-046a5956a686","acronym":"PEDIA","url":"https://clinicaltrials.gov/study/NCT06175637","created_at":"2023-12-20T02:18:58.163Z","updated_at":"2025-02-25T14:10:26.024Z","phase":"","brief_title":"Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs","source_id_and_acronym":"NCT06175637 - PEDIA","lead_sponsor":"AstraZeneca","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 12/20/2023","start_date":" 12/20/2023","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-18"},{"id":"1b444f14-d71f-4564-a2b3-eb610213a4f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04166409","created_at":"2021-01-18T20:19:50.287Z","updated_at":"2025-02-25T15:11:21.327Z","phase":"Phase 3","brief_title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","source_id_and_acronym":"NCT04166409","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • NF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Koselugo (selumetinib) • vincristine"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 01/31/2020","start_date":" 01/31/2020","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-13"},{"id":"5a80093d-379d-4637-97f1-f9c3c20913c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03871257","created_at":"2021-01-18T19:05:20.611Z","updated_at":"2025-02-25T15:11:04.920Z","phase":"Phase 3","brief_title":"A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma","source_id_and_acronym":"NCT03871257","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Koselugo (selumetinib) • vincristine"],"overall_status":"Recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-13"},{"id":"6e8c9c85-9d26-4c35-8860-c80648e49b52","acronym":"","url":"https://clinicaltrials.gov/study/NCT02188264","created_at":"2021-01-18T10:12:45.005Z","updated_at":"2025-02-25T15:25:18.307Z","phase":"Phase 1","brief_title":"Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02188264","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • RAF1 • MAPK1","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • RAF1 • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/29/2014","start_date":" 08/29/2014","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 04/26/2019","study_completion_date":" 04/26/2019","last_update_posted":"2025-02-11"},{"id":"b6564bde-b8d0-4ec2-957a-4f9dc888300c","acronym":"SPRINT","url":"https://clinicaltrials.gov/study/NCT01362803","created_at":"2021-01-18T05:34:38.658Z","updated_at":"2025-02-25T15:25:09.588Z","phase":"Phase 1/2","brief_title":"AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors","source_id_and_acronym":"NCT01362803 - SPRINT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 09/21/2011","start_date":" 09/21/2011","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2032","study_completion_date":" 01/01/2032","last_update_posted":"2025-02-11"},{"id":"5f8b072a-82e7-4058-ac66-89f1f2f42c46","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576117","created_at":"2021-01-18T21:50:45.604Z","updated_at":"2025-02-25T16:32:16.258Z","phase":"Phase 3","brief_title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","source_id_and_acronym":"NCT04576117","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1 • NF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E","tags":["BRAF • IDH1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • vinblastine"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"9ca08e6c-d47d-4698-95f5-d5e3748cdfe5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213691","created_at":"2021-01-18T15:51:28.406Z","updated_at":"2025-02-25T16:44:10.128Z","phase":"Phase 2","brief_title":"Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213691","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-05"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"6d86e75b-88c2-4211-b30c-f46071399e7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01933932","created_at":"2021-01-17T17:38:54.654Z","updated_at":"2025-02-25T17:22:15.826Z","phase":"Phase 3","brief_title":"Assess Efficacy \u0026 Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","source_id_and_acronym":"NCT01933932","lead_sponsor":"AstraZeneca","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Koselugo (selumetinib) • Neulasta (pegfilgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 09/25/2013","start_date":" 09/25/2013","primary_txt":" Primary completion: 06/07/2016","primary_completion_date":" 06/07/2016","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-31"},{"id":"b693b06c-3b76-4750-b15a-1fde2b2e9268","acronym":"SPRINT","url":"https://clinicaltrials.gov/study/NCT02407405","created_at":"2021-01-18T11:29:43.638Z","updated_at":"2025-02-25T17:29:15.429Z","phase":"Phase 2","brief_title":"MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","source_id_and_acronym":"NCT02407405 - SPRINT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/07/2016","start_date":" 01/07/2016","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2025-01-30"},{"id":"fc4f4a2e-e0a6-4bbd-a0f4-00b74d4a19c7","acronym":"SPRINKLE","url":"https://clinicaltrials.gov/study/NCT05309668","created_at":"2022-04-04T13:52:42.080Z","updated_at":"2025-02-25T16:17:32.008Z","phase":"Phase 1/2","brief_title":"Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to \u003c7 Years With NF1-related Symptomatic, Inoperable PN","source_id_and_acronym":"NCT05309668 - SPRINKLE","lead_sponsor":"AstraZeneca","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/21/2022","start_date":" 01/21/2022","primary_txt":" Primary completion: 04/08/2024","primary_completion_date":" 04/08/2024","study_txt":" Completion: 04/28/2028","study_completion_date":" 04/28/2028","last_update_posted":"2024-12-16"},{"id":"b9bf4de0-c370-4a9f-8834-7be7464bc2c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05101148","created_at":"2021-11-01T12:53:14.999Z","updated_at":"2025-02-25T16:16:53.006Z","phase":"Phase 1","brief_title":"Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas","source_id_and_acronym":"NCT05101148","lead_sponsor":"AstraZeneca","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/21/2021","start_date":" 07/21/2021","primary_txt":" Primary completion: 04/06/2022","primary_completion_date":" 04/06/2022","study_txt":" Completion: 01/12/2026","study_completion_date":" 01/12/2026","last_update_posted":"2024-12-10"},{"id":"0e7d88c7-00a3-454e-8a93-465950de8c08","acronym":"KOMET","url":"https://clinicaltrials.gov/study/NCT04924608","created_at":"2021-06-14T18:52:32.218Z","updated_at":"2025-02-25T16:16:22.855Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas","source_id_and_acronym":"NCT04924608 - KOMET","lead_sponsor":"AstraZeneca","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 11/19/2021","start_date":" 11/19/2021","primary_txt":" Primary completion: 08/05/2024","primary_completion_date":" 08/05/2024","study_txt":" Completion: 03/17/2025","study_completion_date":" 03/17/2025","last_update_posted":"2024-12-09"},{"id":"f8aa54b6-cac6-4d9e-ad7f-1c17ff88bf8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04590235","created_at":"2021-01-18T21:53:34.262Z","updated_at":"2025-02-25T16:10:42.940Z","phase":"Phase 1","brief_title":"A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)","source_id_and_acronym":"NCT04590235","lead_sponsor":"AstraZeneca","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 12/16/2020","start_date":" 12/16/2020","primary_txt":" Primary completion: 08/16/2022","primary_completion_date":" 08/16/2022","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-11-19"},{"id":"a32ecad7-5454-46b4-8444-9e5355b8f01d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03162627","created_at":"2021-01-18T15:35:40.609Z","updated_at":"2025-02-25T14:58:06.370Z","phase":"Phase 1","brief_title":"Selumetinib and Olaparib in Solid Tumors","source_id_and_acronym":"NCT03162627","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • HRAS • NF1 • MUC16","pipe":"","alterations":" ","tags":["KRAS • BRAF • HRAS • NF1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/04/2017","start_date":" 08/04/2017","primary_txt":" Primary completion: 08/30/2026","primary_completion_date":" 08/30/2026","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2024-10-16"},{"id":"243bbd2b-9fa8-4a47-8997-af40c6654b26","acronym":"SEL-TH-1601","url":"https://clinicaltrials.gov/study/NCT03095248","created_at":"2021-01-18T15:15:00.040Z","updated_at":"2025-02-25T14:57:54.989Z","phase":"Phase 2","brief_title":"Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors","source_id_and_acronym":"NCT03095248 - SEL-TH-1601","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2024-10-04"},{"id":"ae9e478e-e6fe-4a4a-997a-f85a6be1d091","acronym":"","url":"https://clinicaltrials.gov/study/NCT03801369","created_at":"2021-01-18T18:47:29.710Z","updated_at":"2025-02-25T15:08:15.103Z","phase":"Phase 2","brief_title":"Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03801369","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • ER • PGR • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["HER-2 • ER • PGR • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • Truqap (capivasertib) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-08-13"},{"id":"2ec14da4-befc-40bc-b3f1-e458ba4e38d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05891847","created_at":"2023-06-07T14:07:49.609Z","updated_at":"2024-07-02T16:35:00.403Z","phase":"","brief_title":"Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia","source_id_and_acronym":"NCT05891847","lead_sponsor":"AstraZeneca","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 03/20/2026","primary_completion_date":" 03/20/2026","study_txt":" Completion: 03/20/2026","study_completion_date":" 03/20/2026","last_update_posted":"2024-05-29"},{"id":"8113943a-1cb9-48a3-9fd1-2922c9763160","acronym":"NCI-2018-01098","url":"https://clinicaltrials.gov/study/NCT03581487","created_at":"2021-01-18T17:37:14.416Z","updated_at":"2024-07-02T16:35:01.037Z","phase":"Phase 1/2","brief_title":"Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03581487 - NCI-2018-01098","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Koselugo (selumetinib) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"b3ec16de-b06c-4b4e-97bd-502739a6230d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02664935","created_at":"2021-01-18T12:59:26.753Z","updated_at":"2025-02-25T14:36:10.262Z","phase":"Phase 2","brief_title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02664935","lead_sponsor":"University of Birmingham","biomarkers":" NKX2-1 • TP63","pipe":"","alterations":" ","tags":["NKX2-1 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tagrisso (osimertinib) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Koselugo (selumetinib) • Truqap (capivasertib) • fexagratinib (ABSK091) • ceralasertib (AZD6738) • sitravatinib (MGCD516) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-13"}]